Teva (NYSE:TEVA) said this week that the FDA approved its ProAir Digihaler device – a digital inhaler that uses sensors to connect to a companion mobile app for people with asthma and chronic obstructive pulmonary disease.
The company’s device features built-in sensors that can measure inspiratory flow and detect when the inhaler is used. After the data is sent to a mobile app, the user can review historical data and share it with their healthcare professionals.
Get the full story at our sister site, Drug Delivery Business News.